• Auro del Giglio and Cristina Ito.
• Clínica de Oncologia e Hematologia, São Paulo, Brazil. sandrabr@netpoint.com.br
• Sao Paulo Med J. 2004 May 6; 122 (3): 128130128-30.

ContextPatients with metastatic non-small cell lung cancer are deemed incurable, but they may derive some benefit from systemic palliative chemotherapy. Recently, with the introduction of epidermal growth factor receptor (EGFR) antagonists such as gefitinib (Iressa), an effective and less toxic option is now available for the treatment of such patients.ObjectiveTo assess the activity and toxicity of gefitinib in a group of Brazilian patients.Type Of StudyProspective, open label, non-randomized and non-controlled.SettingClínica de Oncologia e Hematologia (CLIOH), São Paulo, Brazil.Patients And MethodsFrom June 2002 to April 2003 we treated five patients with metastatic previously-treated non-small cell lung cancer (median of two previous chemotherapy regimens), using gefitinib at a dose of 250 mg orally on a daily basis, within a compassionate protocol sponsored by AstraZeneca. The patients' median age was 65 years and two of them were male. Three had a performance status of 1, one of 2 and one of 3, on the ECOG (Eastern Cooperative Oncology Group) scale.ResultsWe observed skin rash in two patients, diarrhea in three and arthralgia in two. One patient had a partial response and another had stabilization of her disease, as measured via imaging studies (which have lasted for more than 11 and 4 months, respectively), which were accompanied by significant decrease in tumor markers, whereas three patients worsened during treatment.DiscussionNew options of chemotherapy agents with favorable toxicity profiles are urgently needed for the treatment of metastatic non-small lung cancer patients who usually have short life expectancies. In our small series of five patients, we observed stabilization of the disease in two of them and the skin and gastrointestinal reactions often described in the literature in all of them. Two had arthralgia, not reported before.ConclusionWe concluded that gefitinib is an important addition to the therapeutic armamentarium for patients with metastatic non-small cell lung cancer.

25 keywords...

hide…